

Subject Index

A
Aclacinomyin A 243
Adenocarcinoma 23
Adjuvant Therapy 139
Androgen Priming 261
Anthracyclines 41, 193
Anti Emetic 133
Autologous Marrow Transplantation 31
AZQ Anaphylaxis 317

B
Bioavailability Absorption Oral or Rectal 93
Brain Tumors 125
Breast Cancer 87, 139
Breast Cancer Phase II 179
Busulphan 3

C
Carcinoma of the Bronchus 31
Cardiotoxicity 193
cis-Diamminedichloride Platinum 27
cis-Dichlorodiammineplatinum II 67
cis-Platinum 267, 281
Chemotherapy 261
Clinical Trials 1
Cloning Human Tumors 99
Colorectal Cancer 35, 199, 293
Cross-Linking 3
Cross-Resistance 163
Cyclophosphamide 31

D
Daunorubicin/DNA Complex 318
2'-Deoxyadenosine 221
Dianhydrogalactitol 125
Dibromodulcitol 125, 171
Dichloromethotrexate 305
Drug Therapy for Refractory AML 73

F
5-FU 17, 87
FAM 277

G
Gastric Carcinoma 277

H
Hematopoietic Tissue 267
Hepatocellular Carcinoma 231, 305
High Dose Cyclophosphamide 311
Human Fibroblast Interferon 47

I
Intrathecal Ara-C 285
Interferon 99
in vitro Degradation 175

K
Kidney 267

L
L-PAM 175

M
Macromolecular Interactions 271
Medroxyprogesterone 77
Melphalan 271
Metabolic Modulation 87
Metabolism 119
Metaclopromide 133
Mice 267
Mitomycin C 189
Mitoxantrone 157, 179
Mitoxantrone Pharmacology 113
Mouse Mammary 23
MPA Pharmacokinetics 151
Murine Experimental Tumor 157
Myeloid Leukemia 255

N
Nephrotoxicity 27
Neurotoxicity 211
Non-Hodgkin's Lymphoma Chemotherapy 237

O
ORG 5895 315
Oxipurinol 93

P
PALA/5-Fu 301
Pentamethyl melamine 105
Peptichemio 9
Pharmacokinetics 105, 189, 193, 211, 215, 271
Pharmacokinetics CSF 251
Pharmacokinetics, TG, β -TGdR 119
Phase I Trial 301
Platinum 67
Prognosis in CGL 205
Prostate Cancer 261

R
Radioactive Estradiol 23
Razoxane 251, 293
Reduced Toxicity MCNU 183
Renal Function 281

S
Sincalide lieus 83
Sugar Alcohol 183

T
Talisomycin 57
Testicular Carcinoma 27
6-Thioguanine 199

U
Uridine Rescue 17

V
Vinblastine Syndrome of Inappropriate ADH Secretion 253
Vinca Alkaloid 163
Vincristine 83, 211, 215
Vindesine 255